The UK government has backed plans to broaden the legal definition of gene therapy medicines to include certain synthetic genetic treatments and newer genome-editing techniques. The changes have not yet become law.

The Medicines and Healthcare products Regulatory Agency (MHRA) announced the decision on 19 November 2026 after a UK-wide consultation conducted jointly with Northern Ireland’s Department of Health. Ministers intend to amend the Human Medicines Regulations 2012, subject to international notification procedures and parliamentary approval.
Why is the UK changing its gene therapy definition?
Gene therapy medicinal products are a type of advanced therapy medicine designed to work through genetic material or genetically modified cells. They are being developed for conditions including inherited disorders and some cancers.
The existing definition largely reflects techniques available when the framework was first developed in 2007. It focuses on biological medicines containing recombinant nucleic acids. More recent medicines may use synthetic genetic material or different genome-editing methods, potentially leaving developers uncertain about how products will be classified.
Under the proposed revision, qualifying products could include medicines containing recombinant or synthetic nucleic acids that undergo transcription or translation, as well as treatments whose mechanism involves deliberate, sequence-specific genome editing. Not every medicine involving genetic material would automatically become a gene therapy product.
What did the consultation find?
The consultation ran from 11 May to 22 June 2026 and received 48 responses. The government reports that 40 respondents, or 83%, supported the proposed changes, while five opposed them. Twelve responses came from individuals and 36 from organisations including pharmaceutical developers, NHS providers, patient groups and professional bodies.
These figures show the views of consultation participants, not a representative survey of the UK public. Some respondents also argued that products with similar biological functions may carry different risks depending on how they are manufactured.
Will the changes make gene therapy treatments available sooner?
The MHRA says the new wording would give developers a clearer regulatory route, which could support research and investment. However, clearer classification does not itself authorise any new medicine or guarantee access through the NHS.
The existing requirements for medicines to demonstrate safety, quality and efficacy will remain in place. Medicines already licensed will not need to be reclassified as a result of the change.
Vaccines used to prevent infectious diseases will continue to be excluded from the gene therapy category. The government has also chosen not to extend the definition to every technology that alters gene activity without editing a genetic sequence.
When will the new gene therapy rules take effect?
There is no confirmed commencement date. The MHRA and Northern Ireland’s Department of Health intend to proceed with secondary legislation, but the amendment remains subject to the necessary procedures and parliamentary approval.
Speaking in the government announcement, MHRA Executive Director Operations Julian Beach said the proposals would address a gap in the existing definition and give developers greater certainty about the licensing requirements they face. The agency also believes the approach could encourage investment, but any benefits to patients remain prospective.
The distinction is important: this is a decision to pursue a change in regulatory definitions, not evidence that a new treatment has been approved or made available to patients.

